Ruben G.W. Quek

HSR26-247: Real-World Quality of Life in Patients Treated With Cemiplimab for Advanced Cutaneous Squamous Cell Carcinoma: Results of CemiplimAb Survivorship Epidemiology (CASE) Study

Guilherme Rabinowits, Soo J. Park, Nikhil I. Khushalani, Timothy Panella et autres

us, pr, jp (code pays fourni par la source)

First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials

Ewa E. Kalinka, Igor Bondarenko, Miranda Gogishvili, Tamar Melkadze et autres

Introduction: Patients with unresectable locally advanced NSCLC who are not candidates for concurrent chemoradiation represent an unmet medical need. We report long-term results for this patient subgroup from two phase III trials. Methods: We analyzed data from patients with locally advanced NSCLC …

pl, ua, us, tr, ru (code pays fourni par la source)

Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors

David R. Gandara, Miranda Gogishvili, Ahmet Sezer, Tamta Makharadze et autres

Introduction There is potential clinical utility in using patient-reported outcomes (PROs) to predict survival in patients with advanced non-small cell lung cancer. We assessed the prognostic value of PROs for survival in two phase 3 cemiplimab studies in advanced non-small cell lung …

us, ge, tr (code pays fourni par la source)

1862P Association between patient-reported outcomes (PROs) and overall survival (OS) in aNSCLC patients treated with first-line (1L) cemiplimab-based therapy

David R. Gandara, Tamta Makharadze, M. Gogishvili, A. Sezer et autres

us, ge, tr, gb (code pays fourni par la source)

1666P CemiplimAb-rwlc survivorship and epidemiology (CASE): A prospective, non-interventional study of the safety and effectiveness of cemiplimab in immunocompromised/immunosuppressed (IC/IS) patients with advanced cutaneous squamous cell carcinoma (CSCC) at 2 years’ follow-up

Soohyung Park, Guilherme Rabinowits, Michael J. Kelley, E. Ruíz et autres

us (code pays fourni par la source)

Evaluating the safety and effectiveness of cemiplimab in combination with platinum-doublet chemotherapy by demographic characteristics in first-line treatment of advanced non-small cell lung cancer: An ongoing multi-database real world evidence study in US patients.

Alexi Archambault, Chao Chen, Alexander Breskin, Ruben G.W. Quek et autres

e20572 Background: The Food and Drug Administration (FDA) has issued guidance urging sponsors to encourage inclusion of underrepresented populations in clinical trials. Non-interventional studies employing real-world (RW) data may be used to evaluate the safety and effectiveness of medicines in populations not …

us (code pays fourni par la source)

Evaluation of current programmed death-ligand 1 (PD-L1) testing practices for metastatic non-small cell lung cancer (mNSCLC): Insights from a large network of US community oncology practices.

Kathleen M. Aguilar, Jessica Paulus, Ruben G.W. Quek, T. Hager et autres

e23294 Background: PD-L1 testing has become crucial for guiding immunotherapy in mNSCLC and evidence suggests increasing adoption of PD-L1 testing in the community oncology setting. This study evaluated current real-world PD-L1 testing patterns in The US Oncology Network to identify opportunities for …

us (code pays fourni par la source)

CemiplimAb-rwlc survivorship and epidemiology (CASE): Interim results from a prospective study of the safety and effectiveness of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC) in a real-world setting.

Soo Jung Park, Guilherme Rabinowits, Timothy J. Panella, Jade Homsi et autres

9533 Background: Cemiplimab is the first PD-L1 inhibitor approved for the treatment of patients with locally advanced (la) or metastatic (m) cutaneous squamous cell carcinoma (CSCC) not amenable to curative therapy. Here, we present an analysis of cemiplimab-treated patients with advanced CSCC …

us (code pays fourni par la source)

Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%

Saadettin Kılıçkap, Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et autres

BACKGROUND: In the phase 3 EMPOWER-Lung 1 study, first-line cemiplimab monotherapy provided significant survival benefit versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%. This exploratory subgroup analysis investigated the clinical outcomes of …

tr, ua, ru, th, us (code pays fourni par la source)

CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma

Soo Jung Park, David M. Ellison, Ryan Weight, Jade Homsi et autres

Patients diagnosed with metastatic basal cell carcinoma (BCC) have a poor prognosis. The current standard of care for adults with locally advanced or metastatic BCC who are not candidates for surgery or radiation therapy is treatment with hedgehog pathway inhibitors (HHIs). For …

us, in (code pays fourni par la source)

Reply to: “Questioning Conclusions and Statements on the German HTA System: A Critical Perspective”

James Harnett, Julien Heidt, Ruben G.W. Quek, Laura Walsh

us (code pays fourni par la source)

Evolving oncology care management trends in the United States: A survey among health care decision makers

Gary M. Oderda, Diana Brixner, Joseph Biskupiak, James Harnett et autres

BACKGROUND: There is limited knowledge of how US managed care professionals view and prioritize quality metrics/performance measures, care models, alternative payment models, and clinical pathways in oncology settings. OBJECTIVE: To characterize payor perspectives on, and the use of, oncology clinical pathways and …

us (code pays fourni par la source)